A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. Efficacy and safety of finenerone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. FIGARO-DKD (finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease).
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease. Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and clinical diagnosis of diabetic kidney disease. FIDELIO-DKD (Finerenone in reducing kidney failure and disease progression in diabetic kidney disease).
A phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of ASP8232 as add-on therapy to angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) in reducing albuminuria in patients with type 2 diabetes and chronic kidney disease.
A phase 3b, multi-center, open-label trial to evaluate the long term safety of titrated immediate-release tolvaptan (OPC 41061, 30 mg to 120 mg/day, split dose) in subjects with autosomal dominant polycystic kidney disease.
A phase 3b, multi-center, randomized-withdrawel, placebo-controlled, double-blind, parallel-group trial to compare the efficacy and safety of tolvaptan (45 to 120 mg/day, split-dose) in subjects with chronic kidney disease between late stage 2 to early stage 4 due to autosomal dominant polycystic kidney disease.
A double-blind, placebo-controlled, randomized, two-stage, parallel-group, adaptive design phase 2a study to evaluate the effects of BMS-813160 in subjects with type 2 diabetes mellitus and diabetic kidney disease (DKD) who have residual macroalbuminuria desprite treatment with an inhibitor of the renin-angiotensin system.
A phase 1b, multicenter, pilot, randomized, double-blind trial to determine the pharmacokinetics and pharmacodynamics of orally administered tolvaptan 3.75, 7.5, and 15 mg tablets in subjects with syndrome of inappropriate antidiuretic hormone secretion.
A randomized, multicountry, multicenter, double-blind, parallel, placebo-controlled study of the effects of Atrasentan on renal outcomes in subjects with type 2 diabetes and nephropathy - SONAR: Study of diabetic nephropathy with Atrasentan.
A phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of FG-4592 in the treatment of anemia in chronic kidney disease patients not on dialysis.
A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subject with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy.
Non-interventional study to evaluate the ease of reaching individual goals in serum phosphorus (Steering).
An observational prostective registry to identify demographic and clinical characteristics of patients hospitalized with euvolemic and hypervolemic hyponatremia and assess the comparative effectiveness of available treatment and the impact on resource utilization.
A multi-centre multi-national observational port-authorisation safety study to document the drug utilisation of Samsca and to collect information on the safety of Samsca when used in routine medical practice.
An open, observational non-interventional study in peritoneal dialysis patients treated with IV iron, Ferinject for anaemia and iron deficiency.
The IMPACT SHPT Study: Study to evaluate the improved management of iPTH with Paricalcitol-centered therapy vs. Cinacalcet Therapy with low-dose Vitamin D in Hemodialysis patients with secondary hyperparathyroidism.
An observational cohort study of extended dosing (Q2W or QM) with Aranesp s.c. in patients with Chronic Kidney Disease not on dialysis (EXTEND).
Evaluation of the clinical use of Mimpara in haemodialysis and peritoneal dialysis patients, an observational study (ECHO).